Invitrogen, Wave Biotech, Thermo, SwissAnalytic Group, Caliper, NovaScreen, Xenogen, ABI, BG Medicine, Digene, Third Wave, Beckman, PerkinElmer, Euroscreen, Evotec Tech, Cepheid, Idaho Technology, BioMerieux, OGT, Agilent, ServiceXS, Bio-Rad, AMEX, Sequen | GenomeWeb
Invitrogen to Make Sales Force Changes
 
Invitrogen, hoping to reverse a $130-million third-quarter loss, will make changes to its sales force leadership and restructure its commission policy, CEO Greg Lucier said last week at the JP Morgan Healthcare Conference in San Francisco.
 
Lucier said Invitrogen will also consolidate its antibody manufacturing process, putting more focus on productivity.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.